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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/ ih jIndia presently leads the world in the prevalence of coronary
heart disease (CHD).1 There are several unique features about the
Asian Indian lipid proﬁle that not only increases the risk of CHD but
also results in the severe prematurity of major adverse cardiovas-
cular events (MACE) compared to the rest of the world. Twenty-
ﬁve percent of myocardial infarctions’ (MI) in India occur in
patients younger than 40 years of age and two-thirds occur before
age 55.2 Asian Indians have on average lower low-density
lipoprotein cholesterol (LDL-C) levels, higher levels of small dense
LDL-C, LDL particles, non-high-density lipoprotein cholesterol
(HDL-C), apolipoprotein B (ApoB), lipoprotein(a) and triglycerides
and the associated lower HDL-C levels, compared with Western
countries.3 There is often the misleading clinical impression due to
lower baseline LDL-C levels in India, that less intensive statin
therapy is required. There is also the concern that due to lower
body mass indexes and common polymorphisms of the statin
metabolic pathways (i.e., CYP 3A4 and C19) in Asian Indians that
lower doses of statins should be utilized to avoid potential adverse
side effects. These issues combined with a lack of clinical trial
safety data in Asian Indians explains the dearth of high dose statin
utilization in India despite large cardiovascular outcome trials
(CVOT) demonstrating the superiority of high over low intensity
statin therapy. In fact, the AHA/ACC 2013 guidelines advocate
either atorvastatin 80 mg or rosuvastatin 40 mg for all patients
with clinical atherosclerotic cardiovascular disease,4 but yet these
doses are under utilized throughout India.
This is why the ROSUVEES-2 trial (Efﬁcacy and Safety of the
Intensive Dose of Rosuvastatin 40 mg/day in Patients with Acute
Coronary Syndrome and at High Risk of Cardiovascular
Disease),5 is a welcome addition to the medical literature to
support the safety and efﬁcacy of the rosuvastatin 40 mg dose
speciﬁcally in an Asian Indian population with a recent acute
coronary syndrome (ACS). Shah and his co-investigators have
documented that rosuvastatin 40 mg can be given to Asian
Indian patients during the hospitalization for an ACS with
excellent LDL-C lowering efﬁcacy, and a very low rate of adverse
side effects. Comparing the ROSUVEES-2 baseline data to the
recently completed IMPROVE-IT trial,6 which was also con-
ducted in an ACS population; validates the differences in the risk
proﬁles for Asian Indians compared to the rest of the world.
Compared to the IMPROVE-IT patients, the ROSUVEES-2
population was 10 years younger (64 vs. 54 years old), HDL-C
was 10 mg/dl lower (48 mg/dl vs. 38 mg/dl), triglycerides 31 mg/
dl higher (137 mg/dl vs. 168 mg/dl) and the inﬂammatory
marker hs-CRP was also higher (6.9 mg/L vs. 3.8 mg/L). Since
most of the residual risk for recurrent events occurs in patientshttp://dx.doi.org/10.1016/j.ihj.2016.09.006
0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).with high triglycerides combined with low HDL-C,7 the
ROSUVEES-2 trial emphasizes the need to maximize the statin
for all patients presenting with an ACS, especially in India.
Higher intensity compared to lower dose statin treatment is
associated with greater reductions in LDL-particles, small LDL-C,
apoB and non-HDL-C in which elevations likely explains much of
the higher residual risk in the Asian Indian population.8–10
Perhaps a good target of therapy for Asian Indian CHD patients
should be the total cholesterol to HDL-C ratio (TC/HDL-C). In the
ROSUVEES-2 trial the baseline TC/HDL-C decreased from 5.1 to
3.7 (p < .001). Most reassuring from the ROSUVEES-2 trial data
was the safety proﬁle of the rosuvastatin 40 mg dose. There
were no adverse effects on CPK, SGOT, SGPT and eGFR. Only 3.5%
of patients (n = 8) had a dose reduction due to myalgias. These
results compare very favorably with the safety and tolerability
of rosuvastatin 40 mg in clinical trials conducted outside of
India. Therefore there appears to be very little need for
additional concerns for utilizing rosuvastatin 40 mg in Asian
Indians compared to patients in the rest of the world.
Hopefully, this new data will reassure clinicians in India to
initiate rosuvastatin 40 mg in their patients during the hospitali-
zation for an ACS. The potential pleotropic effects of statin therapy
in addition to the greater modiﬁcation of atherogenic lipoproteins
by utilizing the higher intensity doses provides an unprecedented
opportunity to maximize residual risk factor modiﬁcation. The
ROSUVEES-2 trial provides the evidence needed to document both
the efﬁcacy and safety of this more aggressive lipid modifying as
well as anti-inﬂammatory approach.
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